The team behind MetaProViz, led by researchers at Heidelberg University and the University of Cologne, including Christina Schmidt, Christian Frezza and Julio Saez-Rodriguez, identified two stubborn obstacles that have long plagued metabolomics analysis. The first is the lack of standardised workflows. Although dozens of tools exist for individual steps, most are available only as web applications whose user-friendly interfaces hide critical parameter settings, undermining the reproducibility standards that modern science demands. The second obstacle is more subtle and arguably more damaging: metabolite annotations are frequently ambiguous. Mass spectrometry cannot reliably distinguish fine structural details such as stereoisomers or constitutional isomers, meaning a detected feature does not correspond to one fully defined chemical structure. Databases compound the problem by storing metabolites at different levels of specificity, so assigning a single unambiguous identifier to every measured peak is often impossible.

MetaProViz tackles these problems with a modular architecture consisting of five interlocking components: pre-processing, differential metabolite analysis, prior knowledge access and integration, functional analysis, and visualisation. The package operates on annotated intensity matrices, the format typically delivered by metabolomics facilities after peak assembly and annotation, and each module can be used interactively or as a building block within larger pipelines. Built-in vignettes with example datasets, automatic logging of parameters, warnings and errors, and publication-ready figures based on ggplot2 make the tool approachable for researchers with minimal coding experience while satisfying the audit trails demanded by experienced bioinformaticians. Automated checks and informative messages guide users through decisions that would otherwise require specialist knowledge, from normalisation strategy to statistical test selection, including Shapiro-Wilk tests that report whether the chosen statistical approach is appropriate for the data at hand.

At the heart of the package lies a curated knowledge resource called MetSigDB, the Metabolism Signature Database. This collection of annotated metabolite sets unifies pathway-metabolite sets from sources such as KEGG, Reactome and WikiPathways, chemical class-metabolite sets, cancer-metabolite sets from MACdb, and metabolite-protein interactions from MetalinksDB covering receptors, transporters and enzymes. MetSigDB also enables conversion of gene sets into metabolite sets using metabolic reactions drawn from a filtered version of the Recon-3D model. Crucially, MetaProViz systematically excludes non-specific metabolites such as water, carbon dioxide and xenobiotics, and its prior knowledge is accessed through the OmniPath ecosystem, giving the tool a sustainable backend that can evolve with the field.

The most technically innovative part of MetaProViz is its handling of metabolite identifier ambiguity, a problem the authors illustrate vividly with the amino acid alanine. When assigning identifiers from the Human Metabolome Database, both D-alanine and L-alanine must be attached because no unspecific HMDB entry exists, whereas ChEBI offers only a single generic identifier that fails to map to most standard pathway databases. Because enzyme stereoselectivity is homochiral, with living systems dominated by L-amino acids and D-sugars, these distinctions matter biologically. MetaProViz addresses the mismatch through an eight-step workflow: quality control of the feature identifier space, counting identifiers per feature, detecting identifier mismatches, translating identifiers from one database to another, traversing a metabolite identifier graph to harvest all connected identifiers, adding equivalent identifiers based on chirality, and then quantifying and flagging mapping ambiguities for manual review.

Applied to a published clear-cell renal cell carcinoma patient dataset, this workflow delivered striking results. Initially only 43 percent of features carried complete assignments across HMDB, KEGG and PubChem, and a quarter of features had nothing but a PubChem identifier. After MetaProViz cleaning, translation and graph traversal, the proportion of fully annotated features rose to 54 percent, dramatically expanding the overlap between measured data and prior knowledge. The team also catalogued the mapping scenarios that can silently distort enrichment analysis, from many-to-one mappings that deflate pathways to one-to-many mappings that inflate them, and flagged sixteen cases in the renal cancer data that required manual review. Without this systematic accounting, over-representation analysis could produce misleading or outright nonsensical conclusions, a known hazard when genomic-style pathway tools are naïvely applied to metabolites.

The package also breaks new ground in exometabolomics, the measurement of metabolites consumed from and released into the culture medium by cells, a capability the authors note is not offered by any other publicly available tool. MetaProViz normalises these data against media blanks and growth factors, yielding negative values for consumed metabolites and positive values for released ones, and replaces classical log2 fold changes with a log2 distance measure that captures the direction of exchange between conditions. Its biological regulatory clustering method, bioRCM, then integrates extracellular consumption-release patterns with intracellular metabolomics through logical regulatory rules, producing clusters of metabolites that carry clear biological meaning.

When the team applied this machinery to renal cancer cell lines, the results were biologically compelling. Primary and metastatic clear-cell renal cell carcinoma cells predominantly consumed amino acids from the medium while healthy renal epithelial cells released them. One cluster of particular interest contained metabolites that were consumed by the cancer cells and simultaneously depleted inside them. Querying this cluster against MetalinksDB revealed methionine as a standout: cancer cells consumed methionine from the media and showed reduced intracellular levels, and tumour tissue from patients similarly exhibited decreased methionine compared with adjacent normal tissue. The authors connect this increased methionine usage to the elevated DNA-hypermethylation landscape characteristic of clear-cell renal cell carcinoma, and the associated enzymes and transporters, including BHMT and SLC43A2, have previously been linked to patient survival. This is precisely the kind of mechanistic hypothesis, linking an extracellular metabolic exchange to an intracellular epigenetic mechanism, that the package was designed to surface.

Beyond cell lines, MetaProViz introduces a metadata analysis method for heterogeneous patient cohorts. By relating principal components of the metabolomics data to clinical variables through analysis of variance, the method identifies which patient characteristics drive metabolic variation. Applied to 138 matched tumour-normal pairs, it confirmed that tissue type and tumour stage explained the largest share of variance, but also revealed that a small percentage of variance in the fourth principal component separated patients by age. Subsequent multi-condition clustering comparing young and old patient subsets uncovered an age-specific signature of dipeptides, upregulated in older patients and downregulated in younger ones, accompanied by altered aminoacyl-tRNA biosynthesis and protein digestion and absorption pathways. The authors suggest such dipeptide patterns could hold promise as biomarkers, and demonstrate that metadata-driven analysis can extract metabolic patterns invisible to classical pathway enrichment alone.

The developers have positioned MetaProViz for the future as well as the present. The package is available through Bioconductor, ensuring reproducible and scalable installation, and the team anticipates integration into workflow management systems such as nf-core modules in Nextflow, which would embed it directly into the pipelines of metabolomics core facilities. As artificial intelligence accelerates metabolite identification through language-model-guided annotation and self-supervised learning of mass spectra, the number of confidently identified metabolites will grow sharply, making rigorous tools for functional interpretation ever more valuable. By combining curated prior knowledge, ambiguity-aware identifier handling, exometabolomics analysis and safeguarded statistics in one flexible framework, MetaProViz offers the metabolomics community what genomics has long enjoyed: a standardised path from raw data to biological understanding, and a systematic way to ask not just which metabolites change, but why it matters.

The statistical machinery underlying MetaProViz reflects a broader lesson about the distinct nature of metabolites as data objects. Unlike genes, whose counts lend themselves to established negative binomial models, metabolite intensities span wide dynamic ranges and their distributions can vary substantially across features, which is why the package evaluates normality per feature and warns users when a chosen test may be inappropriate. The background set problem in over-representation analysis is treated with similar care: because the measured metabolite list is shaped by the extraction method and instrumentation rather than by biology alone, the package allows users to define the statistical universe explicitly, a detail that genomic enrichment tools often take for granted but that can materially alter results in metabolomics.

The methionine findings in clear-cell renal cell carcinoma also sit within a well-documented biological context. Renal cancer cells are known to rely heavily on amino acid uptake, and methionine metabolism feeds directly into the one-carbon cycle that supplies methyl groups for DNA methylation. The observed combination of methionine consumption from the medium, intracellular depletion in tumours, and hypermethylation signatures is therefore internally coherent, and the survival associations reported for the linked enzymes and transporters suggest the pattern may have clinical relevance rather than being a mere artefact of cell culture. The authors are careful to frame these connections as hypotheses for experimental validation, which is precisely the intended output of the functional analysis modules.

The age-specific dipeptide signature uncovered in the patient cohort illustrates another strength of the metadata-driven approach. Dipeptides are products of protein turnover, and altered aminoacyl-tRNA biosynthesis and protein digestion pathways accompanying the age separation point toward shifts in protein metabolism with ageing. Because the analysis of variance framework relates principal components to clinical variables directly, such associations emerge without preselecting metabolites of interest, reducing the risk of confirmation bias. For laboratories adopting the package, the modular design means these analyses can be adopted incrementally, starting with quality control and differential analysis before progressing to prior knowledge integration, making the transition to reproducible metabolomics workflows manageable even for groups without dedicated bioinformatics support.

Subject of Research: An open-source metabolomics data analysis package, MetaProViz, that integrates prior knowledge to generate mechanistic hypotheses.

Article Title: Integrated metabolomics data analysis to generate mechanistic hypotheses with MetaProViz

Article References: Schmidt, C., Franken, J., Turei, D., Prymidis, D., Daley, M., Frezza, C., & Saez-Rodriguez, J. (2026). Integrated metabolomics data analysis to generate mechanistic hypotheses with MetaProViz. Molecular Systems Biology. https://doi.org/10.1038/s44320-026-00231-8

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00231-8

Keywords: metabolomics, MetaProViz, bioinformatics, mass spectrometry, exometabolomics, pathway enrichment, MetSigDB, metabolite identifiers, clear-cell renal cell carcinoma, methionine metabolism, R package, prior knowledge integration